参考文献/References:
[1] Nakamura S.Structure of Azomycin,a new aruibiotic.Pharm Bull,1955,3(5):379-383.
[2] Troost EG,Laverman P,Philippens ME,et al.Correlation of[18F] FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts.Eur J Nucl Med Mol Iamging,2008,35(10):1803-1811.
[3] Valable S,Petit E,Roussel S,et al.Complementary information from magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model.Nucl Med Biol,2011,38(6):781-793.
[4] Rajendran JG,Schwartz DL,0’Sullivan J,et al.Tumor hypoxia imaging with[18F] fluoromisonidazole positron emission tomography in head and neck cancer.Clin Cancer Res,2006,12(18):5435-5441.
[5] Kurihara H,Honda N,Kono Y,et al.Radiolabelled agents for PET imaging of tumor hypoxia.Curr Med Chem,2012,19(20):3283-269.
[6] Yamamoto Y,Maeda Y,Kawat N,et al.Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas.Nucl Med Commun,2012,33(6):621-625.
[7] Hayashi K,Furutsuka K,Takei M,et al.High-yield automated synthesis of[18F] fluoroazomycin arabinoside([18F]FAZA) for hypoxia-specific tumor imaging.Appl Radiat Isot,2011,69(7):1007-1013.
[8] Bouvet VR,Wuest M,Wiebe Li,et al.Synthesis of hypoxia imaging agent 1-(5-deoxy-5-fluoro-α-D-arabinofuranosyl)-2-nitroimidazole using microfluidic technology.Nucl Med Biol,2011,38(2):235-245.
[9] Mortensen LS,Busk M,Nordsmark M,et al.Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes:a preclinical study,Radi other Oncol,2011,99(3):418-423.
[10] Zha Z,Zhu L,Liu Y,et al.Synthesis and evaluation of two novel 2-nitroimidazole derivatives as potential PET radioligands for tumor imaging.Nucl Med Biol,2011,38(4):501-508.
[11] Vercellino L,Groheux D,Thoury A,et al.Hypoxia imaging of uterine cervix carcinoma with 18F-FETNIM PET-CT.Clin Nucl Med,2012,37(11):1065-1068.
[12] Chen L,Zhang Z,Kolb HC,et al.18F-HX4 hypoxia imaging with PET-CT in head and neck cancer:a comparison with 18F-FMISO.Nucl Med Commun,2012,33(10):1096-1102.
[13] Mahy P,De Bast M,Gillart J,et al.Detection of tumour hypoxia:comparison between EF5 adducts and[18F]-EF3 uptake on an individual mouse tumour basis.Eur J Nucl Med Mol Imaging,2006,33(5):553-556.
[14] Mahy P,De Bast M,De Groot T,et al.Comparative pharmacokinetics,biodistribution,metabolism and hypoxia-dependent uptake of[18F]-EF3 and[18F]-MISO in rodent tumor models.Radiother Oncol,2008,89(3):353-360.
[15] Dubois L,Landuyt W,Cloetens L,et al.[18F]EF3 is not superior to[18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.Eur J Nucl Med Mol Imaging,2009,36(2):209-218.
[16] Reischl G,Dorow DS,Cullinance C,et al.Imaging of tumor hypoxia with[124I]IAZA in comparison with[18F]FMISO and[18F]FAZA-first small animal PET results.J Pharm Pharm Sci,2007,10(2):203-211.
[17] Riedl CC,Brader P,Zanzonico P,et al.Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis:a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort.Eur J Nucl Med Mol Imaging,2008,35(1):39-46.
[18] Vera P,Bohn P,Edet-Sanson A,et al.Simultaneous positron emission tomography(PET) assessment of metabolism with 18F-fluoro-2-deoxy-d-glucose(FDG),proliferation with 18F-fluorothymidine(FLT),and hypoxia with 18Fluoro-misonidazole(F-miso) before and during radiotherapy in patients with non-small-cell lung cancer(NSCLC):a pilot study.Radiother Oncol,2011,98(1):109-116.
[19] Christian N,Deheneffe S,Bol A,et al.Is 18F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer 14C-EF3 in animal tumor models,Radiother Oncol,2010,97(2):183-188.
[20] Kaira K,Endo M,Abe M,et al.Biologic correlates of 18F-FDG uptake on PET in pulmonary pleomorphic carcinoma.Lung Cancer,2011,71(2):144-150.
[21] Yoshii Y,Yoneda M,Ikawa M,et al.Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction:studies with mitochondrial DNA-less ρ0 cells and cybrids carrying MELAS mitochondrial DNA mutation.Nucl Med Biol,2012,39(2):177-185.
[22] Dence CS,Ponde DE,Welch MJ,et al.Autoradiographic and small-animal PET comparisons between 18F-FMISO,18F-FDG,18F-FLT and the hypoxia selective 64Cu-ATSM in a rodent model of cancer.Nucl Med Biol,2008,35(6):713-20.
[23] Grigsby PW,Malyapa RS,Hiqashikubo R,et al.Comparison of molecular markers of hypoxia and imaging with 60Cu-ATSM in cancer of the uterine cervix.Mol Imaging Biol,2007,9(5):278-283.
[24] Sun X,Chu T,Wang X.Preliminary studies of 99mTc-BnAO and its analogues:synthesis,radiolabeling and in vitro cell uptake.Nucl Med Biol,2010,37(2):117-123.
[25] Lee BF,Wang LW,Lin SH,et al.Tc-99m-HL91 imaging in the early detection of neuronal injury in a neonatal rat model of hypoxic ischemia.Crit Care Med,2012,40(6):1930-1938.
相似文献/References:
[1]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[2]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[3]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[4]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[5]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[6]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[7]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[8]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[9]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[10]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[11]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[12]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[13]陆东燕,侯莎莎,丁恩慈,等.结核性与恶性腹膜弥漫性病变的18F-FDG PET/CT影像特征分析[J].国际放射医学核医学杂志,2014,38(6):398.[doi:10.3760/cma.j.issn.1673-4114.2014.06.012]
Lu Dong-yan,Hou Sha-sha,Ding En-ci,et al.Analysis of 18F-FDG PET/CT imaging features of tuberculous and cancerous diffuse peritoneal lesions[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):398.[doi:10.3760/cma.j.issn.1673-4114.2014.06.012]
[14]刘春利,李毅红.18F-FDG PET/CT在原发灶不明的脑转移瘤中的诊断价值[J].国际放射医学核医学杂志,2013,37(2):92.[doi:10.3760/cma.j.issn.1673-4114.2013.02.008]
LIU Chun-li,LI Yi-hong.The value of 18F-FDG PET/CT in diagnosing brain metastases from unknown primary tumor[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):92.[doi:10.3760/cma.j.issn.1673-4114.2013.02.008]
[15]王胜军,杨卫东,赵小虎,等.18F-FDG PET/CT诊断多发癌的价值[J].国际放射医学核医学杂志,2013,37(2):96.[doi:10.3760/cma.j.issn.1673-4114.2013.02.009]
WANG Sheng-jun,YANG Wei-dong,ZHAO Xiao-hu,et al.Value of 18F-FDG PET/CT in the diagnosis of multiple primary malignant neoplasms[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):96.[doi:10.3760/cma.j.issn.1673-4114.2013.02.009]
[16]唐宇辉,陈跃.PET/CT在儿科恶性肿瘤中的应用进展[J].国际放射医学核医学杂志,2013,37(2):107.[doi:10.3760/cma.j.issn.1673-4114.2013.02.012]
TANG Yu-hui,CHEN Yue.The progression of PET/CT in pediatric malignant tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):107.[doi:10.3760/cma.j.issn.1673-4114.2013.02.012]
[17]孙爱君,任茜,刘健,等.11C-乙酸盐PET和PET/CT在肿瘤显像中的应用[J].国际放射医学核医学杂志,2013,37(4):243.[doi:10.3760/cma.j.issn.1673-4114.2013.04.013]
SUN Ai-jun,REN Qian,LIU Jian,et al.The application of 11C-acetate PET and PET-CT for tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):243.[doi:10.3760/cma.j.issn.1673-4114.2013.04.013]
[18]辛军,赵周社,李红,等.自适应统计迭代重建技术在PET/CT全身扫描中的应用[J].国际放射医学核医学杂志,2013,37(5):279.[doi:10.3760/cma.j.issn.1673-4114.2013.05.007]
XIN Jun,ZHAO Zhou-she,LI Hong,et al.Adaptive statistical iterative reconstruction technology in the application of PET/CT whole body scans[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):279.[doi:10.3760/cma.j.issn.1673-4114.2013.05.007]
[19]王玉婷,黄钢,蒋瑾,等.18F-FDG PET用于肿瘤治疗疗效评价的meta分析进展[J].国际放射医学核医学杂志,2012,36(6):334.[doi:10.3760/cma.j.issn.1673-4114.2012.06.004]
WANG Yu-ting,HUANG Gang,JIANG Jin,et al.Tumor response monitoring by 18F-FDG PET: updated review of meta-analyses[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):334.[doi:10.3760/cma.j.issn.1673-4114.2012.06.004]
[20]江茂情,吴华.18F-FDG和18F-FLT PET-CT在肿瘤非手术治疗早期疗效评价中的应用[J].国际放射医学核医学杂志,2012,36(6):339.[doi:10.3760/cma.j.issn.1673-4114.2012.06.005]
JIANG Mao-qing,WU Hua.18F-FDG and 18F-FLT PET-CT in evaluation of the early response of malignant tumors after different therapies[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):339.[doi:10.3760/cma.j.issn.1673-4114.2012.06.005]